Effect of preoperative topical nepafenac 0.1% on inflammatory response after uncomplicated cataract surgery in healthy subjects.
Administration, Topical
Aged
Anti-Inflammatory Agents, Non-Steroidal
/ administration & dosage
Benzeneacetamides
/ administration & dosage
Cataract Extraction
Dose-Response Relationship, Drug
Female
Follow-Up Studies
Humans
Male
Phenylacetates
/ administration & dosage
Postoperative Complications
/ prevention & control
Preoperative Care
/ methods
Prospective Studies
Tomography, Optical Coherence
Treatment Outcome
Visual Acuity
cataract surgery
flare
non-steroidal anti-inflammatory drugs
postoperative inflammation
Journal
Acta ophthalmologica
ISSN: 1755-3768
Titre abrégé: Acta Ophthalmol
Pays: England
ID NLM: 101468102
Informations de publication
Date de publication:
Feb 2021
Feb 2021
Historique:
received:
26
10
2019
accepted:
19
05
2020
pubmed:
20
6
2020
medline:
7
9
2021
entrez:
20
6
2020
Statut:
ppublish
Résumé
To determine the effect of preoperative topical Nepafenac administration on anterior chamber flare after uneventful cataract surgery in healthy subjects. Prospective randomized clinical trial. Seventy-three eyes of 73 healthy patients undergoing routine cataract surgery were randomized to receive (group A) topical nepafenac (1 mg/ml) or not to receive (group B) 1 drop 3 times per day for 3 days before surgery. All eyes received the same postoperative anti-inflammatory therapy. Clinical outcome parameters such as best corrected visual acuity, intraocular pressure, retinal central foveal thickness and aqueous flare were recorded preoperatively, 1, 15, 30 and 60 days after surgery. Three patients were excluded for poor compliance, and three patients were excluded or developing pseudophakic macular oedema during the follow-up. Both groups were comparable for age, gender, and showed similar BCVA, intraocular pressure and central macular thickness values preoperatively and during the entire follow-up (p > 0.01). Aqueous flare values showed a statistically increase in both groups respect to preoperative values through follow-up evaluations (p < 0.01), while values were significantly lower in group A than in group B 30 days after surgery (p < 0.01). Preoperative administration of topical Nepafenac reduces the inflammatory response in healthy patients undergoing uncomplicated cataract surgery one month after surgery respect to non-treated group.
Substances chimiques
Anti-Inflammatory Agents, Non-Steroidal
0
Benzeneacetamides
0
Phenylacetates
0
nepafenac
0J9L7J6V8C
Types de publication
Journal Article
Randomized Controlled Trial
Langues
eng
Sous-ensembles de citation
IM
Pagination
e70-e73Informations de copyright
© 2020 Acta Ophthalmologica Scandinavica Foundation. Published by John Wiley & Sons Ltd.
Références
Chu CJ, Johnston RL, Buscombe C, Sallam AB, Mohamed Q & Yang YC (2016): Risk factors and incidence of macular edema after cataract surgery: a database study of 81984 eyes. Ophthalmology 123(2): 316-323.
Danni R, Viljanen A, Aaronson A & Tuuminen R. (2019): Preoperative anti-inflammatory treatment of diabetic patients does not improve recovery from cataract surgery when postoperatively treated with a combination of prednisolone acetate and nepafenac. Acta Ophthalmol 97(6): 589-595.
Donnenfeld ED, Perry HD, Wittpenn JR, Solomon R & Nattis A, Chou T (2006): Preoperative ketorolac tromethamine 0.4% in phacoemulsification outcomes: pharmacokinetic-response curve. J Cataract Refract Surg 32, 1474-1482.
Ersoy L, Caramoy A, Ristau T, Kirchhof B & Fauser S (2013): Aqueous flare is increased in patients with clinically significant cystoid macular oedema after cataract surgery. Br J Ophthalmol 97: 862-865.
Gulkilik G, Kocabora S, Taskapili M & Engin G (2006): Cystoid macular edema after phacoemulsification: risk factors and effect on visual acuity. Can J Ophthalmol 41: 699-703.
Henderson BA, Kim JY, Ament CS, Ferrufino-Ponce ZK & Grabowska A, Cremers SL (2007): Clinical pseudophakic cystoid macular edema. Risk factors for development and duration after treatment. J Cataract Refract Surg 33, 1550-1558.
Hoffman RS, Braga-Mele R, Donaldson K et al.; ASCRS Cataract Clinical Committee and the American Glaucoma Society. K (2016): Cataract surgery and nonsteroidal anti-inflammatory drugs. J Cataract Refract Surg 42: 1368-1379.
Hunter AA, Modjtahedi SP, Long K, Zawadzki R, Chin EK, Caspar JJ, Morse LS & Telander DG (2014): Improving visual outcomes by preserving outer retina morphology in eyes with resolved pseudophakic cystoid macular edema. J Cataract Refract Surg 40: 626-631.
Kessel L, Tendal B, Jørgensen KJ, Erngaard D, Flesner P, Andresen JL & Hjortdal J (2014): Post-cataract prevention of inflammation and macular edema by steroid and nonsteroidal anti-inflammatory eye drops. Ophthalmology 121: 1915-1924.
Kim SJ, Schoenberger SD, Thorne JE, Ehlers JP, Yeh S & Bakri SJ (2015): Topical nonsteroidal anti-inflammatory drugs and cataract surgery: a report by the American Academy of ophthalmology. Ophthalmology 122: 2159-2168.
Kim BZ, Patel DV & McGhee CN (2017): Auckland cataract study 2: clinical outcomes of phacoemulsification cataract surgery in a public teaching hospital. Clin Exp Ophthalmol 45: 584-591.
McCafferty S, Harris A & Kew C (2017): Pseudophakic cystoid macular edema prevention and risk factors; prospective study with adjunctive once daily topical nepafenac 0.3% versus placebo. BMC Ophthalmol 17: 16.
Miyake K, Ota I, Miyake G & Numaga J (2011): Nepafenac 0.1% versus fluorometholone 0.1% for preventing cystoid macular edema after cataract surgery. J Cataract Refract Surg 37: 1581-8.
Packer M, Lowe J & Fine H (2012): Incidence of acute postoperative cystoid macular edema in clinical practice. J Cataract Refract Surg 38: 2108-2111.
Riley AF, Malik TY, Grupcheva CN, Fisk MJ, Craig JP & McGhee CN (2002): The Auckland cataract study: co-morbidity, surgical techniques, and clinical outcomes in a public hospital service. Br J Ophthalmol 86: 185-190.
Roberts CW (1996): Pretreatment with topical diclofenac sodium to decrease postoperative inflammation. Ophthalmology 103: 636-9.
Singh R, Alpern L & Jaffe GJ (2012): Evaluation of nepafenac in prevention of macular edema following cataract surgery in patients with diabetic retinopathy. Clin Ophthalmol 6: 1259-1269.
Stock G, Ahlers C, Dunavoelgyi R, Kahraman G, Schauersberger J, Schmidt-Erfurth U & Amon M (2011): Evaluation of anterior segment inflammation and retinal thickness change following cataract surgery. Acta Ophthalmol 89: 369-375.
Tranos PG, Wickremasinghe SS, Stangos NT, Topouzis F, Tsinopoulos I & Pavesio CE (2004): Macular edema. Surv Ophthalmol 49: 470-490.
Ursell PG, Spalton DJ, Whitcup SM & Nussenblatt RB (1999): Cystoid macular edema after phacoemulsification: relationship to blood-aqueous barrier damage and visual acuity. J Cataract Refract Surg 25: 1492-7.
Yavas GF, Ozturk F & Kusbeci T (2007): Preoperative topical indomethacin to prevent pseudophakic cystoid macular edema. J Cataract Refract Surg 33: 804-7.